COST-EFFECTIVENESS OF GRAZOPREVIR / ELBASVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS

被引：0
|
作者：
Mattingly, T. J., III [1 ]
Slejko, J. F. [1 ]
Mullins, C. D. [1 ]
机构：
[1] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.396
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN47
引用
收藏
页码：A415 / A415
页数：1
相关论文
共 50 条
  • [21] Elbasvir and grazoprevir for the treatment of hepatitis C
    Wang, Szu-Jen
    Huang, Chung-Feng
    Yu, Ming-Lung
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2021, 19 (09) : 1071 - 1081
  • [22] The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
    Myers, RP
    Gregor, JC
    Marotta, PJ
    HEPATOLOGY, 2000, 31 (04) : 834 - 839
  • [23] Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
    Kwo, Paul
    Gane, Edward J.
    Peng, Cheng-Yuan
    Pearlman, Brian
    Vierling, John M.
    Serfaty, Lawrence
    Buti, Maria
    Shafran, Stephen
    Stryszak, Paul
    Lin, Li
    Gress, Jacqueline
    Black, Stuart
    Dutko, Frank J.
    Robertson, Michael
    Wahl, Janice
    Lupinacci, Lisa
    Barr, Eliav
    Haber, Barbara
    GASTROENTEROLOGY, 2017, 152 (01) : 164 - +
  • [24] Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population
    Choi, Debra T.
    Puenpatom, Amy
    Yu, Xian
    Erickson, Kevin F.
    Kanwal, Fasiha
    El-Serag, Hashem B.
    Kramer, Jennifer R.
    ANTIVIRAL RESEARCH, 2020, 174
  • [25] Cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
    Jacobs, RJ
    Koff, RS
    HEPATOLOGY, 2000, 32 (04) : 873 - 874
  • [26] Cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
    Myers, RP
    Gregor, JC
    Marotta, PJ
    GASTROENTEROLOGY, 1999, 116 (04) : A1252 - A1252
  • [27] Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4
    El Kassas, Mohamed
    Elbaz, Tamer
    Abd El Latif, Yasmeen
    Esmat, Gamal
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (11) : 1413 - 1421
  • [28] Elbasvir/Grazoprevir (Zepatier) for Hepatitis C
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1489): : 25 - 27
  • [29] Cost-effectiveness of elbasvir/grazoprevir plus sofosbuvir for the treatment of chronic HCV genotype 3 infection in Argentina
    Bissio, E.
    Nwankwo, C.
    Corman, S.
    Monsanto, H.
    Montes, J. L.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S189 - S190
  • [30] Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam
    Nwankwo, Chizoba
    Corman, Shelby L.
    Elbasha, Elamin H.
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2019, 12 (04) : 502 - 508
12345